We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -106.00 | -0.87% | 12,050.00 | 12,036.00 | 12,038.00 | 12,178.00 | 12,010.00 | 12,092.00 | 1,635,146 | 16:35:23 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.34 | 186.61B |
From May 2019 to May 2024
By Tapan Panchal
LONDON--AstraZeneca PLC (AZN.LN) said Tuesday that it has entered into a licensing agreement with Ironwood Pharmaceuticals Inc. (IRWD) for the exclusive U.S. rights to Zurampic, a drug used for the treatment of gout, a type of arthritis.
AstraZeneca said the contract includes rights to the fixed-dose combination of lesinurad and allopurinol used for treating gout. AstraZeneca plans to submit the fixed-dose combination program for U.S. Food and Drug Administration review in the second half of 2016.
Under the agreement, Ironwood will pay AstraZeneca sales-related and other milestone payments of up to $265 million and royalties on product sales. AstraZeneca will manufacture and supply Zurampic, provide certain support and services to Ironwood, and undertake the regulatory approval process.
The agreement doesn't affect AstraZeneca's financial guidance for 2016.
AstraZeneca's shares at 0839 GMT traded 1.1% lower at 4,036 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
April 26, 2016 05:13 ET (09:13 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
